Weight Loss Injections After Major Trauma (Webinar Video)
This is a summary of the webinar, presented by Sheri Taylor, Dietitian and Director of Specialist Nutrition Rehab, which explores the safety, effectiveness, risks, and clinical considerations of GLP-1 and GIP/GLP-1 weight‑loss injections (e.g., liraglutide, semaglutide, tirzepatide) for clients recovering from brain injury, spinal cord injury, and complex trauma.
Sheri outlines how these medications work, who is eligible for them, their benefits, and their significant risks – especially for vulnerable clients in case management and litigation settings.
Timestamps
05:00 – 15:00: How GLP-1 / GIP Weight‑Loss Injections Work
15:00 – 25:00: Effectiveness, Expected Weight Loss & Common Side Effects
25:00 – 35:00: Risks & Contraindications
35:00 – 45:00: Assessment Before Prescribing
45:00 – 55:00: Muscle & Bone Loss (Lean Mass Concerns)
55:00 – 65:00: Nutrition & Diet Considerations
65:00 – 75:00: High‑Risk Situations
75:00 – 85:00: Discontinuation, Weight Regain & Titration
85:00 – End: Costs, MDT Approach & Ethical Concerns
Summary
How the medications work
- They mimic gut hormones GLP-1 (and in some products, GIP) to regulate appetite, slow stomach emptying, influence brain reward pathways, and improve blood glucose control.
- Effects include reduced appetite, altered taste perception, and shifts away from high-fat, high-sugar foods.
Expected weight‑loss outcomes
- Lifestyle only: ~3–10% body weight loss
- Lifestyle + semaglutide: ~10–13%
- Lifestyle + tirzepatide: ~10–20%
- Most weight loss occurs within 6 months, with a plateau at ~18 months.
Benefits
- Improved blood glucose regulation
- Reduced cardiovascular risk
- Significant potential for remission of type 2 diabetes (if ~15% weight loss achieved)
- Reduced sleep apnoea, blood pressure, knee pain and reflux at various weight‑loss thresholds
Risks & side effects
Common:
- Nausea, vomiting, diarrhoea, constipation
Serious:
- Gallbladder disease
- Gastroparesis
- Acute kidney injury
- Pancreatitis
- Hypoglycaemia (even without diabetes)
- Potential progression of diabetic retinopathy
These risks matter especially for trauma clients, who often take multiple medications and already have compromised gut motility.
Concerns for post‑trauma clients
Many clients already have (as a result of their trauma):
- Sarcopenia (low muscle mass)
- Low bone density
- Neurogenic bowel or impaired gut function
- Reduced mobility and activity
- Malnutrition despite appearing overweight
Because GLP‑1 drugs reduce appetite and slow digestion, they can worsen:
- Muscle loss
- Bone loss
- Malnutrition
- Constipation or bowel dysfunction
- Recovery after wounds or surgery
Lean mass loss
Weight loss from GLP‑1 medications includes muscle loss:
- Liraglutide: up to 60% of weight lost is lean mass
- Semaglutide: up to 40%
- Tirzepatide: up to 26%
This is especially problematic for clients already struggling to regain mobility or function after trauma.
Ethical & safety issues
Sheri highlights the dangers of:
- Online pharmacies prescribing without human assessment
- Clients (especially impulsive or cognitively impaired individuals) self‑purchasing injections
- Black‑market or counterfeit products
- Lack of MDT oversight
Elective surgery considerations
Clients must come off GLP‑1 medications before surgery due to:
- Slower gastric emptying increasing aspiration risk
- Higher rates of pneumonia
- Possible impaired bone healing after spinal surgeries
Cost & discontinuation
- Approx. £4,000 per year for medication alone
- Full MDT support can bring costs to ~£21,000 in the first year
- 50–66% stop treatment after 1 year
- 85% stop by 2 years
- Most regain ⅔ of weight within a year of stopping; almost all within two years
Final message
GLP‑1 medications must only be used:
- As an adjunct to comprehensive lifestyle intervention
- After a thorough MDT assessment the factors in both the benefits AND the risks
- With close supervision by dietitians, physios, psychologists, and medical professionals